9/3/2023 0 Comments Accurip trial versiondemand for Wegovy and Ozempic, the respective brand names for semaglutide sold as once-weekly injections for treating obesity and diabetes. The Danish company has had supply issues and struggled to keep up with soaring U.S. and European regulatory approval of the high-dose pill later this year, but timing of a market launch is "to be determined," according to Mico Guevarra, medical director at Novo Nordisk. SAN DIEGO, June 26 (Reuters) - Novo Nordisk (NOVOb.CO) on Sunday said a late-stage trial found that a high-dose oral version of its drug semaglutide helped overweight or obese adults lose 15% of their body weight, which is in line with recent results for other experimental obesity pills.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |